ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,569.90
0.00%
S&P ASX All Technology
2,968.80
0.00%
Brent Oil
83.54
-2.74%
US Dollar vs AUD
1.53185
-0.80%
Bitcoin
57,967.02
-4.35%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. NeuroSense Therapeutics Ltd (NRSN)

  7. NeuroSense Therapeutics Ltd (NRSN) News

NRSN NeuroSense Therapeutics Ltd

1.26
-0.09 (-6.67%)
After Hours
Last Updated: 08:30:10
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
NeuroSense Therapeutics Ltd NRSN NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
Upgrade Icon
-0.09 -6.67% 1.26 08:30:10
Open Price Low Price High Price Close Price Previous Close
1.37 1.24 1.42 1.26 1.35
more quote information »

Recent News

Date Time Source Heading
22/4/202422:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
18/4/202422:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
12/4/202422:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
11/4/202409:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
09/4/202422:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
06/4/202400:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
23/2/202400:25EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
22/2/202400:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
14/2/202405:20EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202402:14EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
08/2/202401:38EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/2/202401:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
10/1/202400:49EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/1/202400:48EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/1/202400:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
28/12/202309:03EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
28/12/202309:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/12/202309:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
22/12/202300:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/12/202308:30EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
15/12/202301:41EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
15/12/202301:24PRNUSNeuroSense Reports New Data: Statistically Significant..
06/12/202307:15EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/12/202307:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/12/202300:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/12/202300:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
05/12/202316:15EDGAR2Form EFFECT - Notice of Effectiveness
05/12/202308:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
04/12/202322:17EDGAR2Form POS AM - Post-Effective amendments for registration..
29/11/202301:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202300:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
22/11/202302:36EDGAR2Form POS AM - Post-Effective amendments for registration..
14/11/202301:28EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/11/202301:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
10/11/202301:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
07/11/202300:35EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/11/202300:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
02/11/202300:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
17/10/202323:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/10/202323:30PRNUSNeuroSense CEO Provides Q3 2023 Update
05/10/202300:12EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/10/202300:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
03/10/202302:39EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202323:16EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202323:05PRNUSEuropean Medicines Agency Grants NeuroSense SME Status
19/9/202323:15EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/9/202323:00PRNUSNeuroSense Granted Patents in Europe, Japan, and Israel for..
14/9/202323:00PRNUSNeuroSense to Participate in Upcoming ALS Conferences:..
12/9/202323:20EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/9/202306:31EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]

Your Recent History

NASDAQ
NRSN
NeuroSense Therapeutics
Delayed Upgrade Clock
ADVFN Logo

Australia
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved